JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) Fair Value & Analysis
Consumer Defensive · TH · Market cap 845M THB
Fair value as of: Jul 15, 2026
From 16 valuation models · updated 26 days ago
Fair value updated Jul 15, 2026, revised from 2.90 THB to 2.43 THB (−16.2%) since Jun 24, 2026. Share price +1.7% over the past month.
A solid business, screening 35% undervalued on our models.
What matters now
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from 1.82 THB (bear) to 3.04 THB (bull), base 2.43 THB. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 55/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
57‑month range 1.50 THB – 9.61 THB · fair‑value band 1.82 THB – 3.04 THB · the 1.80 THB price screens below the 2.43 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) currently trades at 1.80 THB, while our model-based Fair Value estimate is 2.43 THB, implying the stock looks roughly 35.0% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, JSP Pharmaceutical Manufacturing (Thailand) Public Co generated revenue of 1.0B THB at a net margin of 6.0%. Revenue declined 9.9% year over year. It earns a return on equity of 4.6%. Net debt stands at 333M THB. Fundamentals as of Jul 15, 2026
Our scenario range runs from 1.82 THB (bear case) to 3.04 THB (bull case); at 1.80 THB, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at 35%, JSP screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (2.90 THB) versus Economic Profit (0.2600 THB). Highest evidence: Residual Income (76).
Notify me when JSP reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. engages in the research, development, manufacturing, and sales of pharmaceutical, dietary supplementary, traditional medicine, and herbal products in Thailand.
Full company description
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. engages in the research, development, manufacturing, and sales of pharmaceutical, dietary supplementary, traditional medicine, and herbal products in Thailand. It is also involved in manufacturing and selling hemodialysis products and supplies, purified water systems for industrial purposes, and related medical supplies; and services of laboratory research, scientific test and analysis, training and seminar, and consultancy for research fund application businesses. In addition, the company sells products through vending machines. JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. was founded in 1954 and is headquartered in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JSP Pharmaceutical Manufacturing (Thailand) Public Co reported revenue of 1.0B THB in FY2025 versus 422M THB in FY2021, a compound +24.4%/yr. Reported net income was 67.9M THB in FY2025, compounding +23.0%/yr from FY2021.
Watch JSP: get an alert when its fair value changes →
Peer Group
Packaged Foods · 649 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé India Limited NESTLEIND | ₹1,427 | ₹362.37 | -75% |
| Britannia Industries Limited BRITANNIA | ₹5,413 | ₹1,870 | -65% |
| Tata Consumer Products Limited TATACONSUM | ₹1,089 | ₹327.27 | -70% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 6,650 IDR | 15,757 IDR | +137% |
| Samyang Foods Co 003230 | 1,139,000 KRW | 1,010,543 KRW | -11% |
| Patanjali Foods Limited PATANJALI | ₹413.80 | ₹157.04 | -62% |
| Vietnam Dairy Products Joint Stock Company VNM | 58,500 VND | 68,259 VND | +17% |
| PT Mayora Indah Tbk, MYOR | 1,750 IDR | 2,699 IDR | +54% |
| PT Cisarua Mountain Dairy Tbk CMRY | 4,490 IDR | 4,355 IDR | -3% |
| Nongshim Co 004370 | 348,500 KRW | 530,619 KRW | +52% |
Compare JSP Pharmaceutical Manufacturing (Thailand) Public Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) overvalued or undervalued?
What is the fair value of JSP?
What is the quality score of JSP?
What is the revenue of JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP)?
What is the net profit margin of JSP?
Does JSP Pharmaceutical Manufacturing (Thailand) Public Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track JSP Pharmaceutical Manufacturing (Thailand) Public Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.